Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 210-431-8 | CAS number: 615-50-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Basic data given, comparable to guideline/standards
- Principles of method if other than guideline:
- Acute oral toxicity or LD50 value was determined by oral administration of test substance to five dose groups of rats. Subsequently, observations of effects such as clinical signs, cage side observation and mortality are made for 14 d. The test method employed in this study is comparable to OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Remarks:
- pre-dates GLP
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: CFY strain
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Not reported
- Age at study initiation: Not reported
- Weight at study initiation: 98-120 g
- Fasting period before study: Overnight before treatment
- Housing: Not reported
- Diet: Not reported
- Water: Not reported
- Acclimation period: Not reported
ENVIRONMENTAL CONDITIONS: No details on environmental condition were provided in the report - Route of administration:
- oral: gavage
- Vehicle:
- other: aqueous sodium sulphite (0.05%)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 10% Toluene-2, 5-diamine
- Amount of vehicle: 2.5 mL/kg bw
- Justification for choice of vehicle: Not reported
- Lot/batch no.: Not reported
- Purity: Not reported
MAXIMUM DOSE VOLUME APPLIED: 0.64-2.5 mL/kg bw
DOSAGE PREPARATION: 10% solution of test substance was prepared in aqueous sodium sulphite (0.05%) - Doses:
- 0, 64, 100, 160, and 250 mg/kg bw
- No. of animals per sex per dose:
- Five males and five females
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 d
- Frequency of observations and weighing: Daily for 14 days, body weights were taken prior to dosing, and on 7th and 14th day of dosing.
- Necropsy of survivors performed: Yes
- Other examinations performed: Clinical signs of toxicity, mortality, Autopsy of animals died during the study. - Statistics:
- The LD50 and its 95% confidence limits were calculated by the method of Weil C.S. (1952) Biometrics 8, 249.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 102 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 69 - 152
- Mortality:
- 3/5 males and 0/5 females at 64 mg/kg
4/5 males and 3/5 females at 100 mg/kg
0/5 males and 5/5 females at 160 mg/kg
5/5 males and 4/5 females at 250 mg/kg
No mortality with vehicle control - Clinical signs:
- other: Signs of reaction to treatment, observed shortly after dosing, which included: lethargy, piloerection, ataxia and increased salivation. These sign were accompanied by increased respiratory rate in rats treated at 100mg/kg and decreased respiratory rate in
- Gross pathology:
- Mortality was observed within 1 h to 22 h of treatment. Autopsy of these animals revealed slight heamorrhage of the lungs, pallor of the spleen, darkening of the liver and injection of peritoneal blood vessels.
Terminal autopsy findings were normal - Other findings:
- - Recovery of animals: Recovery of survivors, as judged by external appearance and behavior, was apparently complete within 5 days of treatment.
- Organ weights: Not reported
- Histopathology: Not reported
- Potential target organs: Not reported - Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- The acute oral LD50 of Toluene-2, 5-diamine in 0.05% aqueous sodium sulphite vehicle was determined to be 102 mg/kg bw (95% CI= 69-150 mg/kg bw).
- Executive summary:
The acute oral toxicity of Toluene-2, 5-diamine was determined following OECD Guideline 401 (Acute Oral Toxicity)
The study was designed to determine acute oral LD50 of Toluene-2, 5-diamine in 0.05% aqueous sodium sulphite vehicle when dosed to group of rats by oral gavage.
The study involved 5 groups of 10 rats each (5 males / 5 females) weighing 98 to 120 g, starved overnight before treatment with group specific concentration (0, 64, 100, 160 and 250 mg/kg bw) of Toluene-2, 5-diamine.
The selection of various concentrations was based on results from preliminary (range finding) study which indicated that median lethal oral dose (LD50) was in range of 64 to 250 mg/kg bw.
Post treatment, rats were observed for 14 days to record mortality and signs of toxicity. All rats that died during observation period were examined macroscopically to identify the target organ and those surviving were sacrificed terminally to detect possible residual damage.
Signs of toxicity were observed shortly after treatment and included lethargy, piloerection, ataxia and increased salivation. These signs were accompanied by increased respiratory rate in rats treated at 100mg/kg and decreased respiratory rate in rats treated above 100 mg/kg bw. Mortality was observed within 1 h to 22 h of treatment. Autopsy revealed slight heamorrhage of the lungs, pallor of the spleen, darkening of the liver and injection of peritoneal blood vessels. However, terminal autopsy findings of surviving animals were normal.
The recovery of surviving animals was apparently complete within 5 d of treatment as exhibited by external appearance and behavior. A slight depression in body weight gain during first week was observed in female rats treated with 64 and 100 mg/kg bw and all surviving male rats. However, bodyweight gain returned to normal during second week.
The acute median oral LD50 of Toluene-2, 5-diamine in 0.05% aqueous sodium sulphite vehicle was found to be 102 mg/kg bw (95% CI= 69-150 mg/kg bw).
Reference
Table1: Mortality data for group of rats dosed orally with toluene-2,5-diamine (range finding study) (study # 71169)
Dosage (mg/kg bw) |
Mortality ratio (no. of deaths/no. of animal dosed) |
Time of death after dosing |
||
Male |
Female |
Combined |
||
0 |
0/2 |
0/2 |
0/4 |
- |
64 |
0/2 |
0/2 |
0/4 |
- |
250 |
2/2 |
1/2 |
3/4 |
<21 h |
1000 |
2/2 |
2/2 |
3/4 |
<2 h |
- The result of preliminary range finding study indicated that median lethal oral dose (LD50) was in range of 64 to 250 mg/kg bw
Table 2: Mortality ratio and of group mean bw (g) of rats dosed orally with toluene-2,5-diamine (study # 71169)
Sex |
Dosage |
Bodyweight (g) at |
Mortality ratio (no. of deaths/no. of animal dosed) |
Time of death after dosing |
||
Dosing |
1 wk |
2 wk |
||||
Male |
0 |
101 |
177 |
222 |
0/5 |
|
64 |
112 |
178 |
229 |
3/5 |
< 22 h |
|
100 |
102 |
167 |
234 |
4/5 |
< 2 h |
|
160 |
116 |
174 |
242 |
0/5 |
|
|
250 |
106 |
Died |
|
5/5 |
< 21 h |
|
Female |
0 |
106 |
153 |
171 |
0/5 |
|
64 |
113 |
148 |
172 |
0/5 |
|
|
100 |
107 |
136 |
174 |
3/5 |
< 2 |
|
160 |
104 |
Died |
|
5/5 |
< 22 |
|
250 |
106 |
152 |
180 |
4/5 |
< 21 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 102 mg/kg bw
- Quality of whole database:
- reliability 2
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- calculation (if not (Q)SAR)
- Adequacy of study:
- weight of evidence
- Study period:
- 2012
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable calculated/extrapolated data
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- To assess the acute inhalational toxicity of toluene-2,5-diamine (free base and sulphate salt), a kinetic based calculation was done. The kinetic data were derived from various kinetic studies, and the details of the test methods and the results are provided in this summary (refer to executive summary for details). The derived data were consistent with the determined acute toxicity values (derived by in-vivo studies) from p-phenylenediamine, the most appropriate analogue for toluene-2,5-diamine.
- Test type:
- other: Estimated data by calculation
- Limit test:
- no
- Sex:
- not specified
- Dose descriptor:
- LC50
- Effect level:
- 0.99 mg/L air
- Based on:
- other: kinetic based calculation
- Exp. duration:
- 4 h
- Remarks on result:
- other: The calculated inhalational LC50 of 0.99 mg/L for toluene-2,5-diamine is comparable to the determined value for p-phenylenediamine (0.92 mg/L)
- Sex:
- not specified
- Dose descriptor:
- LC50
- Effect level:
- 1.77 mg/L air
- Based on:
- other: kinetic based calculation
- Exp. duration:
- 4 h
- Remarks on result:
- other: The calculated inhalational LC50 of 1.77 mg/L for toluene-2,5-diamine sulphate salt is comparable to the determined value for p-phenylenediamine (0.92 mg/L)
- Interpretation of results:
- Category 4 based on GHS criteria
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- Based on the available acute oral toxicity and kinetic data for toluene-2,5-diamine, the extrapolated acute inhalation toxicity (4 h, LC50) of toluene-2,5-diamine was 0.99 mg/L for the free base and 1.77 mg/l for the sulphate salt. This value is comparable to the determined value for p-phenylenediamine (0.92 mg/L).
- Executive summary:
To assess the acute inhalational toxicity of toluene-2,5-diamine (free base and sulphate salt) , a kinetic based calculation was done. The kinetic data were derived from various kinetic studies, and the details of the test methods and the results are provided in the SCCS Opinion 1479/12, 26 – 27June 2012.In addition, the calculated data for toluene-2,5-diamine (free base and the sulphate salt) were compared with those of the most appropriate analogue, the p-phenylenediamine (refer to below table).
COLIPA Number
Chemical Name
CAS Number
Acute Toxicity
Oral
LD50
Dermal
LD50
Inhalation LC50
Colipa No. A005
Toluene-2,5-Diamine
95-70-5 (free base)
102 mg/kg bw
(rat)
> 2000 mg/ kg bw
(rat, extrapolated)
0.99 mg/l,
(4h, rat, extrapolated)
Colipa No. A005
Toluene-2,5-diaminesulphate
615-50-9
183 mg/kg bw
(rat, extrapolated)
> 2000 mg/kg bw
(rat, extrapolated)
1.77 mg/L,
(4h, rat, extrapolated)
Colipa No. A007
p-Phenylenediamine
106-50-3 (free base)
80-100 mg/kg bw
(rat)
> 7940 mg/kg bw
(male/female rabbit)
0.92 mg/l air
(4 h ,rat)
Studies used for the determination of acute toxicity of TOLUENE-2,5-DIAMINE:
Conversion Factor between the free base and the sulphate salt:
The toxic potential of both forms of 2 Toluene-2,5-diamine is attributable to the free base component. Therefore, study results derived with one of the two forms of Toluene-2,5-diamine, namely the free base or the sulphate salt, can be converted to the other form by applying a conversion factor that is related to the molecular weight and content of the free base in each form.
Molar Masssulfate: 218.23 g/mol
Molar Massfree base: 122.71 g/mol
Conversion factor free base → sulphate = 1.79
Conversion factor sulphate →free base = 0.56
Acute Oral Toxicity study result
LD50oral: 102 mg/kg bw in the rat (CFY strain); “The acute median lethal oral dose was calculated to be 102 mg/kg bw (95% confidence limits of 69-152 mg/kg bw)”.The study was carried out with the free base.
LD50oral=102 mg/kg bw (Toluene-2,5-Diamine)
Conversion factor free base→sulphate = 1.78628
LD50oral=182 mg/kg bw (Toluene-2,5-Diamine Sulphate)
Toxicokinetic study results in Sprague Dawley rats:
Dose levels:
IV: 2.5 mg/kg bw
Oral: 2.5, 25 mg/kg bw
Dermal:0.5 mg/cm² equal to 33.3 mg/kg bw
Bioavailability, assuming 100% bioavailability IV
Oral dosing: 69%
Dermal dosing: 2%
The studies are summarized as follows in SCCS 1479/12:
“In toxicokinetic studies with Sprague-Dawley rats the comparison of AUCs showed differences between oral (25 mg/kg bw: 112 mgeqx h/l) and dermal application (33 mg/kg bw in formulation: 2.27 mgeqx h/l). Following 2.5 mg/kg bw the AUC was 8.53 mgeqx h/l. The bioavailability (derived from comparison to iv administration) after oral dosing of 10 mg/kg bw was 69% while 2% bioavailability was found after dermal administration in a formulation.”The Studies were carried out with the sulphate salt.
This summary provides calculation ofextrapolation of the acute inhalation toxicity of toluene-2,5-diamine. The summary of calculation of extrapolation of the acute dermal toxicity is provided under section 7.2.3 of IUCLID.
Extrapolation of the acute inhalational toxicity of TOLUENE-2,5-DIAMINE:
Required maximum exposure concentration to test material (OECD 403): 5 mg/L
Assumed body weight of the rat for the calculation: 250 g
Respiratory volume of the rat: 0.074 L/min
Required duration (OECD 403): 4 h
Ventilation in 4 hours 0.074 L/min x 60 min x 4 hour = 17.76L
Toluene-2,5-diamine LD50oral = 102 mg/kg bw in the ratwith the free base
Calculation:
Maximum achievable exposure regarding required 5 mg/L for 4 hours (OECD 403):
Exposure during 4 hours:17.76 L x 5 mg/L = 88.8 mg/rat
88.8 mg/0.250 kg bw = 355 mg/kg bw maximum achievable exposure
Oral Bioavailability = 69% (at 25 mg/kg bw, using the data from the toxicokinetic study in Sprague Dawley rats)
Inhalation Bioavailability: Assumed to be 100%
Determination of the correction factor oral vs. inhalation route:
69% oral vs. 100% inhalation = 0.69
LC50 calcinhal. free base: 102 mg/kg bw x 0.250 kg bw x 0.69/17.76 L = 0.99 mg/L
LC50 calcinhal. free base: 0.99 mg/L x 1.79 (conversion free base to sulphate) = 1.77 mg/L
LC50inhal. forp-phenylenediamine = 0.92 mg/L
LC50 calcinhal. for toluene-2,5-diamine = 0.99 mg/L free base
LC50 calcinhal.Toluene-2,5-diamine = 1.77 mg/l sulphate salt
The calculated LC50for toluene-2,5-diamine, namely 0.99 mg/L for the free base and 1.77 mg/L for the sulphate saltcomparable to the determined value forp-phenylenediamine (0.92 mg/L)
The calculated inhalation toxicity value for toluene-2,5-diamine is in the same order of magnitude (0.99 mg/lfor the free base and 1.77 mg/L for the sulphate salt) as the official classification of Acute Tox Cat 4; H332 in Annex VI of the CLP regulation which is being applied in case of 1 mg/L<LC50≤5 mg/L (for dusts/mists).
ASSESSMENT OF VALIDITY:
Since the Weight of Evidence Approach (WoE) used was considered as sufficiently robust to determine the acute inhalation toxic potential of toluene-2,5-diamine, the performance of an animal test for hazard identification purposes was considered to be not justified.
In addition the completion of acute toxicity studies on toluene-2,5-diamine as an ingredient used in cosmetic products would not be considered to comply with the EU regulations regarding animal testing. Furthermore, applying WoE complies with the REACH regulation to avoid animal testing. The validity of the WoE/extrapolation approach used in order to estimate the acute toxicity potential of toluene-2,5-diamine by inhalation route was finally confirmed by the comparison of the extrapolated values on toluene-2,5-diamine with experimental values obtained on the primary member of the p-phenylenediamine family, p-phenylenediamine.
In conclusion, the extrapolated acute inhalation toxicity (4 h, LC50) of toluene-2,5-diamine was 0.99 mg/Lfor the free base and 1.77 mg/L for the sulphate salt. This value is comparable to the determined value for p-phenylenediamine (0.92 mg/L)
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 990 mg/m³ air
- Quality of whole database:
- reliability 2
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- calculation (if not (Q)SAR)
- Adequacy of study:
- weight of evidence
- Study period:
- 2012
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable calculated/extrapolated data
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- To assess the acute dermal toxicity of toluene-2,5-diamine(free base and sulphate salt), a kinetic based calculation was done. The kinetic data were derived from various kinetic studies, and the details of the test methods and the results are provided in this summary (refer to executive summary for details). The derived data were consistent with the determined acute toxicity values (derived by in-vivo studies) from p-phenylenediamine, the most appropriate analogue for toluene-2,5-diamine.
- Test type:
- other: Estimated data by calculation
- Limit test:
- no
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 3 519 mg/kg bw
- Based on:
- other: kinetic based calculation
- Remarks on result:
- other: The calculated dermal LD50 for toluene-2,5-diamine can be assumed to be > 2000 mg/kg bw, which is consistent with the LD50 dermal for the analogue, p-phenylenediamine
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 6 299 mg/kg bw
- Based on:
- other: kinetic based calculation
- Remarks on result:
- other: The calculated dermal LD50 for toluene-2,5-diamine (sulphate form) can be assumed to be > 2000 mg/kg bw, which is consistent with the LD50 dermal for the analogue, p-phenylenediamine
- Interpretation of results:
- GHS criteria not met
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- Based on the available acute oral toxicity and kinetic data for toluene-2,5-diamine, the extrapolated acute dermal toxicity of toluene-2,5-diamine can be assumed to be around 3519 mg/kg bw for the free base and 6299 mg/kg bw for the sulphate salt, while the determined LD50 dermal for p-phenylenediamine is > 7940 mg/kg bw.
In conclusion, the LD50 dermal for both forms of toluene-2,5-diamine is >2000 mg/kg bw. - Executive summary:
To assess the acute dermal toxicity of toluene-2,5-diamine, a kinetic based calculation was done. The kinetic data were derived from various kinetic studies, and the details of the test methods and the results are provided in the SCCS Opinion 1479/12, 26 – 27June 2012. In addition, the calculated data for toluene-2,5-diaminewere compared with those of the most appropriate analogue, the p-phenylenediamine (refer to below table)
COLIPA Number
Chemical Name
CAS Number
Acute Toxicity
Oral
LD50
Dermal
LD50
Inhalation LC50
Colipa No. A005
Toluene-2,5-Diamine
95-70-5 (free base)
102 mg/kg bw
(rat)
> 2000 mg/ kg bw
(rat, extrapolated)
0.99 mg/l,
(4h, rat, extrapolated)
Colipa No. A005
Toluene-2,5-Diamine sulphate
615-50-9
183 mg/kg bw (rat, extrapolated)
> 2000 mg/kg bw (rat, extrapolated)
1.77 mg/L, (4h, rat, extrapolated)
Colipa No. A007
p-phenylenediamine
106-50-3 (free base)
80-100 mg/kg bw
(rat)
> 7940 mg/kg bw
(male/female rabbit)
0.92 mg/L air
(4 h ,rat)
.
Studies used for the determination of acute toxicity of TOLUENE-2,5-DIAMINE:
Conversion Factor between the free base and the sulphate salt:
The toxic potential of both forms of 2 Toluene-2,5-diamine is attributable to the free base component. Therefore, study results derived with one of the two forms of Toluene-2,5-diamine, namely the free base or the sulphate salt, can be converted to the other form by applying a conversion factor that is related to the molecular weight and content of the free base in each form.
Molar Masssulfate: 218.23 g/mol
Molar Massfree base: 122.71 g/mol
Conversion factor free base → sulphate = 1.79
Conversion factor sulphate →free base = 0.56
Acute Oral Toxicity study result
LD50oral: 102 mg/kg bw in the rat (CFY strain); “The acute median lethal oral dose was calculated to be 102 mg/kg bw (95% confidence limits of 69-152 mg/kg bw)”.The study was carried out with the free base.
LD50oral=102 mg/kg bw (Toluene-2,5-Diamine)
Conversion factor free base→sulphate = 1.78628
LD50oral=182 mg/kg bw (Toluene-2,5-Diamine Sulphate)
Toxicokinetic study results in Sprague Dawley rats:
Dose levels:
IV: 2.5 mg/kg bw
Oral: 2.5, 25 mg/kg bw
Dermal:0.5 mg/cm² equal to 33.3 mg/kg bw
Bioavailability, assuming 100% bioavailability IV
Oral dosing: 69 %
Dermal dosing: 2 %
The studies are summarized as follows in SCCS 1479/12:
“In toxicokinetic studies with Sprague-Dawley rats the comparison of AUCs showed differences between oral (25 mg/kg bw: 112 mgeqx h/l) and dermal application (33 mg/kg bw in formulation: 2.27 mgeqx h/l). Following 2.5 mg/kg bw the AUC was 8.53 mgeqx h/l. The bioavailability (derived from comparison to iv administration) after oral dosing of 10 mg/kg bw was 69% while 2% bioavailability was found after dermal administration in a formulation.”
This summary provides calculation ofextrapolation of the acute dermal toxicity of toluene-2,5-diamine. The summary of calculation of extrapolation of the acute inhalation toxicity is provided under section 7.2.2 of IUCLID.
Extrapolation of the acute dermal toxicity of TOLUENE-2,5-DIAMINE:
TOLUENE-2,5-DIAMINELD50oral = 102 mg/kg bw in the ratwith the free base
Oral bioavailability = 69% (at 25.0 mg/kg bw, using the data from the toxicokinetic study in Sprague Dawley rats)
Dermal bioavailability =2% (at 33.3 mg/kg bw)
Calculation:
Determination of the correction factor oral vs. dermal route
69 % oral vs. 2 % dermal = 34.5 (69 : 2 = 34.5)
LD50 calcdermal free base: 102 mg/kg bw x 34.5 = 3519 mg/kg bw
LD50 calcdermal sulphate: 3519 mg/kg bw x 1.79 (conversion free base to sulphate) = 6299 mg/kg bw
Thus, the calculated LD50dermal for toluene-2,5-diamine is 3519 mg/kg bw for the free base and 6299 mg/kg bw for the sulphate salt, while the determined LD50dermal for p-phenylenediamine is > 7940 mg/kg bw. This extrapolation is further supported by a dermal acute toxicity study carried out in rabbits. Even if this study was considered as insufficient for a determination of the dermal LD50of TOLUENE-2,5-DIAMINE (no accordance to any guideline, not GLP compliant, no study report available, only citation of a publication, rated as Klimisch 4), the derived LD50 of >5000 mg/kg bw is in accordance with the calculated values of 3519 mg/kg bw for the free base and 6299 mg/kg bw for the sulphate salt for TOLUENE-2,5-DIAMINE.
The calculated dermal toxicity is >2000 mg/kg for both forms of TOLUENE-2,5-DIAMINE (free base and sulphate salt) and does not support the official classification of toluene-2,5-diamine as Acute Tox Cat 4; H312. The calculated classification as not harmful in contact with skin is the same as that determined for the analogue p-phenylenediamine based on a rat study.However, the latter also in contrast to the official classification of p-phenylenediamine as Acute Tox 3;H311 in Annex VI of the CLP regulation. Moreover, the official classification of toluene-2,5-diaminefor acute dermal and inhalation toxicityas laid down in Annex VI of the CLP regulation is not based on animal data, as stated by the ECHA.
ASSESSMENT OF VALIDITY:
Since the Weight of Evidence Approach (WoE) used was considered as sufficiently robust to determine the acute dermal toxic potential of toluene-2,5-diamine, the performance of an animal test for hazard identification purposes was considered to be not justified.
Based on the REACH regulation “REACH VO - Annex VIII, 8.5.3., (3).), testing of the dermal route is only required, if there is a potential for a significant rate of absorption through the skin. The ADME data demonstrated, that the oral bioavailability of toluene-2,5-diamine in rats is 34.5 times higher than the dermal bioavailability
In addition, the completion of acute toxicity studies on toluene-2,5-diamine as an ingredient used in cosmetic products would not be considered to comply with the EU regulations regarding animal testing. Furthermore, applying WoE complies with the REACH regulation to avoid animal testing. The validity of the WoE/extrapolation approach used in order to estimate the acute toxicity potential of toluene-2,5-diamine by dermal routes was finally confirmed by the comparison of the extrapolated values on toluene-2,5-diamine with experimental values obtained on the primary member of the p-phenylenediamine family, p-phenylenediamine.
Based on the available acute oral toxicity and kinetic data for toluene-2,5-diamine, the extrapolated acute dermal toxicity of toluene-2,5-diamine can be assumed to be around 3519 mg/kg bw for the free base and 6299 mg/kg bw for the sulphate salt, while the determined LD50 dermal for p-phenylenediamine is > 7940 mg/kg bw.
In conclusion, the LD50dermal for both forms of toluene-2,5-diamine can be assumed to be > 2000 mg/kg bw, which is consistent with the LD50dermal for the analogue, namely p-phenylenediamine.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 6 299 mg/kg bw
- Quality of whole database:
- reliability 2
Additional information
Acute oral toxicity or LD50 value was determined by oral administration of test substance to five dose groups of rats. Subsequently, observations of effects such as clinical signs, cage side observation and mortality are made for 14 d. The test method employed in this study is comparable to OECD Guideline 401 (Acute Oral Toxicity). The LD 50 = 102 mg/kg bw that mean that the subsnace is harmful by ingestion.
Based on the available acute oral toxicity and kinetic data for toluene-2,5-diamine, the extrapolated acute dermal toxicity of toluene-2,5-diamine can be assumed to be around 3519 mg/kg bw for the free base and 6299 mg/kg bw for the sulphate salt.
Based on the available acute oral toxicity and kinetic data for toluene-2,5-diamine, the extrapolated acute inhalation toxicity (4 h, LC50) of toluene-2,5-diamine was 0.99 mg/L. This value is comparable to the determined value for p-phenylenediamine (0.92 mg/L). It indicate an harmful effect by inhalation
Justification for selection of acute toxicity – oral endpoint
Acute oral toxicity or LD50 value was determined by oral
administration of test substance to five dose groups of rats.
Subsequently, observations of effects such as clinical signs, cage side
observation and mortality are made for 14 d. The test method employed in
this study is comparable to OECD Guideline 401 (Acute Oral Toxicity)
Justification for selection of acute toxicity – inhalation endpoint
Based on the available acute oral toxicity and kinetic data for
toluene-2,5-diamine, the extrapolated acute inhalation toxicity (4 h,
LC50) of toluene-2,5-diamine was 0.99 mg/L. This value is comparable to
the determined value for p-phenylenediamine (0.92 mg/L).
Justification for selection of acute toxicity – dermal endpoint
Based on the available acute oral toxicity and kinetic data for
toluene-2,5-diamine, the extrapolated acute dermal toxicity of
toluene-2,5-diamine can be assumed to be around 3519 mg/kg bw for the
free base and 6299 mg/kg bw for the sulphate salt.
Justification for classification or non-classification
Acute oral toxicity or LD50 value was determined by oral administration of test substance to five dose groups of rats. Subsequently, observations of effects such as clinical signs, cage side observation and mortality are made for 14 d. The test method employed in this study is comparable to OECD Guideline 401 (Acute Oral Toxicity). The LD 50 = 102 mg/kg bw that mean that the substance is toxic cat 3 by ingestion according to CLP.
Based on the available acute oral toxicity and kinetic data for toluene-2,5-diamine, the extrapolated acute dermal toxicity of toluene-2,5-diamine can be assumed to be around 3519 mg/kg bw for the free base and 6299 mg/kg bw for the sulphate salt.
Based on the available acute oral toxicity and kinetic data for toluene-2,5-diamine, the extrapolated acute inhalation toxicity (4 h, LC50) of toluene-2,5-diamine was 0.99 mg/L. This value is comparable to the determined value for p-phenylenediamine (0.92 mg/L). It indicate an harmful effect by inhalation, warning cat 4 according to CLP
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.